Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer | RxWiki

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Overview[ - collapse ][ - ]

Purpose	Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity.
Condition	Metastatic Breast Cancer
Intervention	Drug: Abraxane Drug: Carboplatin
Phase	Phase 2
Sponsor	Duke University
Responsible Party	Duke University
ClinicalTrials.gov Identifier	NCT01207102
First Received	September 10, 2010
Last Updated	July 9, 2013
Last verified	July 2013

Tracking Information[ + expand ][ + ]

First Received Date	September 10, 2010
Last Updated Date	July 9, 2013
Start Date	August 2011
Estimated Primary Completion Date	December 2014
Current Primary Outcome Measures	PFS [Time Frame: PFS is defined as the interval from study registration to disease progression or death due to any cause, whichever comes first] [Designated as safety issue: No]The primary objective of the trial is to statistically test whether Abraxane® and carboplatin can improve progression-free survival (PFS) as compared to historical controls.
Current Secondary Outcome Measures	To assess the safety and tolerability of a combination regimen of weekly Abraxane® and carboplatin to treat women with "triple negative" Stage IV metastatic breast cancer [Time Frame: 2 years] [Designated as safety issue: Yes]The proportion of patients experiencing any neurotoxicity will be tabulated by grade. The proportion of patients experiencing ≥ grade 3 non-hematologic toxicities (excluding neurotoxicity) and the proportion of patients experiencing ≥ grade 3 hematologic toxicities will be calculated with their exact 80% confidence intervals.

Descriptive Information[ + expand ][ + ]

Brief Title	Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Official Title	A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer
Brief Summary	Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity.
Detailed Description	Paclitaxel and cisplatin are well-recognized for their activity in treating a variety of tumors including breast cancer. As cytotoxins, they have been studied alone and in combination with other chemotherapeutic agents, and have been incorporated into treatment regimens for women who fail previous anthracycline-based therapies. Although both agents are notable for favorable response rates, they are also associated with a variety of adverse events, some of which may be dose-limiting and having a negative effect on quality of life: myelosuppression, nausea and vomiting, diarrhea, stomatitis/mucositis, short- and long-term neuropathy, nephrotoxicity, alopecia and hypersensitivity reactions. As second-generation compounds, Abraxane® and carboplatin have been shown to improve response rates and may mediate some of the toxicities associated with paclitaxel and cisplatin, respectively. Of particular interest is Abraxane's potential to reduce allergic reactions associated with other taxanes. This study combines these two agents: primarily, to evaluate progression-free survival; and secondarily, to assess the feasibility and tolerability of this regimen to treat poor prognosis metastatic breast cancer patients.
Study Type	Interventional
Study Phase	Phase 2
Study Design	Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition	Metastatic Breast Cancer
Intervention	Drug: Abraxane Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days Other Names: paclitaxel protein-bound particles for injectable suspensionDrug: Carboplatin area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days Other Names: Paraplatin
Study Arm (s)	Experimental: Abraxane, Carboplatin Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle

Recruitment Information[ + expand ][ + ]

Recruitment Status	Active, not recruiting
Estimated Enrollment	70
Estimated Completion Date	December 2014
Estimated Primary Completion Date	December 2013
Eligibility Criteria	Inclusion Criteria: - Patients with histologically or cytologically confirmed diagnosis of metastatic (Stage IV) breast cancer; - Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST); - "Triple negative" disease defined as "tumor demonstrating no expression for estrogen, progesterone or HER2 receptors." (No expression is categorized as ≤ 10% of cells staining or Allred ≤ 2); - Aged 18 years or older; - Eastern Cooperative Oncology Group (ECOG)ECOG/Zubrod performance status of 0 or 1; life expectancy ≥ 3 months; - No prior chemotherapy for metastatic disease. - At least 6 months must have elapsed since prior adjuvant chemotherapy. - Laboratory tests performed within 14 days of study entry showing: - Granulocytes ≥ 1,500/µL; - Platelets ≥ 100,000/µL; - Hemoglobin ≥ 9.0 gm/dL; - Total bilirubin ≤ institutional upper limit of normal (ULN); - Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN; - Alkaline phosphatase ≤ 5 times ULN; - Estimated creatinine clearance ≥ 60 mL/min. - Urine protein:creatinine ratio ≤ 1.0. or 24 hour urine protein collection demonstrating ≤ 1 gram of protein per 24 hours to be eligible. - left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan (MUGA)/Echocardiogram; - Informed consent to receive protocol treatment: - Cognitive and communication skills adequate to comply with study and/or follow-up procedures; - Geographic proximity and ability to comply with weekly study visits for the duration of the treatment; - No reproductive potential: - If pre-menopausal - Negative serum pregnancy test within 3 days prior to initiation of protocol-based treatment and patient agrees to use contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of protocol treatment; - If post-menopausal - Amenorrhea for ≥ 12 months or follicle stimulating hormone (FSH) within post menopausal range. Exclusion Criteria: - Pregnant or breast feeding. - Prior treatment with Abraxane® or carboplatin. - Prior chemotherapy for metastatic breast cancer. - Known hypersensitivity to any component of any study drug. - Active infection. - Current neuropathy ≥ grade 2. - central nervous system (CNS) metastases as determined by head CT with contrast or head MRI. - Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months. - Uncontrolled serious contraindicated medical condition or illness.
Gender	Female
Ages	18 Years
Accepts Healthy Volunteers	No
Contacts	Not Provided
Location Countries	United States, China

Administrative Information[ + expand ][ + ]

NCT Number	NCT01207102
Other Study ID Numbers	Pro00019321
Has Data Monitoring Committee	No
Information Provided By	Duke University
Study Sponsor	Duke University
Collaborators	Celgene Corporation
Investigators	Study Chair: Kimberly L Blackwell, MD Duke University
Verification Date	July 2013

Locations[ + expand ][ + ]